Clinical Trial Update: Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis [Phase 1, Phase 2]

View source ↗

Summary

Imatinib mesylate was evaluated in a Phase 1/2 study for desmoid-type fibromatosis, and the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoid-type Fibromatosis

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: UNICANCER | Conditions: Desmoid Tumor | Phase 1, Phase 2 | Status: COMPLETED